Last Updated on March 11, 2021 by The Health Master
The audit of the company”s active pharmaceutical ingredients (API) manufacturing plant at Middleburg, New York has been completed by the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a regulatory filing.
“We have been issued a Form 483 with 3 (three) observations. We will address them comprehensively within the stipulated timeline. Currently, we do not have any sales from this plant,” it added.
As per the USFDA, Form 483 is issued to firm management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related acts.
Shares of the company on Wednesday ended 1.15 per cent up at Rs 4,498.65 apiece on the BSE.